JP2006523238A5 - - Google Patents

Download PDF

Info

Publication number
JP2006523238A5
JP2006523238A5 JP2006509820A JP2006509820A JP2006523238A5 JP 2006523238 A5 JP2006523238 A5 JP 2006523238A5 JP 2006509820 A JP2006509820 A JP 2006509820A JP 2006509820 A JP2006509820 A JP 2006509820A JP 2006523238 A5 JP2006523238 A5 JP 2006523238A5
Authority
JP
Japan
Prior art keywords
ring
compound according
optionally substituted
atoms
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006509820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523238A (ja
JP4895806B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/010858 external-priority patent/WO2004092196A2/en
Publication of JP2006523238A publication Critical patent/JP2006523238A/ja
Publication of JP2006523238A5 publication Critical patent/JP2006523238A5/ja
Application granted granted Critical
Publication of JP4895806B2 publication Critical patent/JP4895806B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006509820A 2003-04-09 2004-04-08 Ｔｉｅ−２モジュレータと使用方法 Expired - Fee Related JP4895806B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46144603P 2003-04-09 2003-04-09
US60/461,446 2003-04-09
PCT/US2004/010858 WO2004092196A2 (en) 2003-04-09 2004-04-08 Tie-2 modulators and methods of use

Publications (3)

Publication Number Publication Date
JP2006523238A JP2006523238A (ja) 2006-10-12
JP2006523238A5 true JP2006523238A5 (enExample) 2007-06-28
JP4895806B2 JP4895806B2 (ja) 2012-03-14

Family

ID=33299811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509820A Expired - Fee Related JP4895806B2 (ja) 2003-04-09 2004-04-08 Ｔｉｅ−２モジュレータと使用方法

Country Status (6)

Country Link
US (1) US7763627B2 (enExample)
EP (1) EP1610774A4 (enExample)
JP (1) JP4895806B2 (enExample)
AU (2) AU2004230928B2 (enExample)
CA (1) CA2520323C (enExample)
WO (1) WO2004092196A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7880000B2 (en) 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
CA2584485C (en) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
WO2006071095A1 (en) * 2004-12-31 2006-07-06 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
EP1909788A2 (en) 2005-07-29 2008-04-16 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
AU2009262252B2 (en) 2008-06-26 2013-05-02 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2010045095A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
WO2010111063A1 (en) 2009-03-21 2010-09-30 Ning Xi Amino ester derivatives, salts thereof and methods of use
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
CN102574817A (zh) 2009-09-24 2012-07-11 巴斯夫欧洲公司 用于抵抗无脊椎动物害虫的氨基喹唑啉化合物
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
AU2012330885B2 (en) 2011-11-01 2016-10-06 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9914730B2 (en) * 2012-09-28 2018-03-13 Cancer Research Technology Limited Azaquinazoline inhibitors of Atypical protein Kinase C
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
CA2969839A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
EP3226868A4 (en) 2014-12-05 2018-08-15 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
WO2017004405A1 (en) * 2015-07-01 2017-01-05 Northwestern University Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
MA45244A (fr) 2016-06-13 2019-04-17 Cancer Research Tech Ltd Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
CA3059939A1 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
KR20200035029A (ko) * 2017-06-30 2020-04-01 더 유니버시티 오브 노스캐롤라이나 앳 채플 힐 이질염색질 유전자 억제 저해제
SG11202103796TA (en) * 2018-10-16 2021-05-28 Ikena Oncology Inc Indole ahr inhibitors and uses thereof
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
EP4100395A4 (en) * 2020-02-04 2024-03-06 Trobio Therapeutics Pty Ltd Quinazoline compounds and the use thereof in the treatment of cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
FR2263750A1 (en) * 1974-03-12 1975-10-10 Delalande Sa N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc.
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
DE19904710A1 (de) * 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
NZ518702A (en) * 1999-11-17 2004-04-30 Dainippon Pharmaceutical Co [5-chloro-6-phenyl-2-(4-trifluoromethylphenyl)-4-pyrimidinylamino]acetamide derivatives, process for producing the same, medicinal compositions containing the same and intermediate of these compounds
DK1246623T3 (da) * 1999-12-02 2006-11-13 Osi Pharm Inc Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
ATE346064T1 (de) * 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
CN1474815A (zh) * 2000-09-20 2004-02-11 Ĭ��ר���ɷ����޹�˾ 4-氨基-喹唑啉
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
JPWO2002051836A1 (ja) * 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives
PE20021011A1 (es) * 2001-03-23 2003-02-01 Bayer Corp Derivados quinazolinicos como inhibidores de la rho-quinasa
WO2003026661A1 (fr) * 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
DE60236322D1 (de) * 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
WO2004081009A1 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors

Similar Documents

Publication Publication Date Title
JP2006523238A5 (enExample)
JP2008525526A5 (enExample)
JP2010526800A5 (enExample)
JP2015143283A5 (enExample)
JP2010506942A5 (enExample)
JP2018526413A5 (enExample)
ATE383358T1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
JP2016505012A5 (enExample)
JP2007510665A5 (enExample)
JP2014051526A5 (enExample)
JP2008525417A5 (enExample)
JP2010510237A5 (enExample)
WO2008057862A3 (en) MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
JP2020536863A5 (enExample)
JP2013528180A5 (enExample)
RU2007124545A (ru) Производные [4-(гетероарил)пиперазин-1-ил]-(2,5-замещенный фенил)метанона в качестве ингибиторов переносчика глицина-1 (glyt-1) для лечения неврологических и психоневрологических заболеваний
UA103894C2 (ru) Соединения и способ для снижения уровня мочевой кислоты
JP2013509392A5 (enExample)
RU2013141274A (ru) Содержащие фосфор соединения в качестве ингибиторов протеинкиназ
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2007523941A5 (enExample)
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
RU2012103460A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ИМИДАЗО{1,2-a}ПИРИМИДИН-5-ОНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В ФАРМАЦИИ
JP2010529144A5 (enExample)
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения